Yuhan Corporation is trading at 57,600 KRW, down 1.54% from the previous day as of 10:21 AM on the 4th. The trading volume is 341,995 shares, which is 15.56% of the previous day's volume. Yuhan Corporation is known as a leading domestic pharmaceutical company specializing in prescription drugs.

On August 3rd, researchers Mi-hwa Seo and Hye-in Lee from Yuanta Securities projected a 3.2% growth in sales and assumed the possibility of receiving additional milestone payments (16 billion KRW milestone related to Janssen’s Phase 3 clinical trial initiation). They noted that clinical trials for new drug pipelines such as Lazertinib and NASH treatments are progressing smoothly, increasing the likelihood of milestone receipts. They set Yuhan Corporation’s target price at 64,000 KRW.

Over the past five days, individual investors have net purchased 292,136 shares of Yuhan Corporation, while foreign investors and institutions have net sold 148,412 shares and 185,818 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing